SCHEMBL4629034

SCHEMBL4629034

O=c1[nH]cc(-c2ccco2)c(=O)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
LMNA P02545 3/20 0.45
ADORA1 P30542 2/20 0.41
TMIGD3 P0DMS9 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
GLA P06280 2/20 0.40
RECQL P46063 2/20 0.40
BLM P54132 2/20 0.40
KMT2A Q03164 2/20 0.40
PKM P14618 1/20 0.40
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
DPYD Q12882 2/20 0.38
ATAD2 Q6PL18 1/20 0.38
CYP19A1 P11511 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24186016 0.81 NT5E (0.48) ALDH1A1LMNAADORA1TMIGD3KDM4E
SCHEMBL5801644 0.73 ALDH1A1 (0.64) ALDH1A1LMNAGAAMAPTDPYD
SCHEMBL7747485 0.70 MEN1 (0.42) ALDH1A1LMNAADORA1TMIGD3KDM4E
SCHEMBL6112463 0.70 ALDH1A1 (0.43) ALDH1A1LMNAGAAMAPTDPYD
SCHEMBL3485414 0.69 ALDH1A1 (1.00) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL5797995 0.69 ALDH1A1 (0.39) ALDH1A1LMNAMEN1BLMKMT2A
SCHEMBL23611453 0.68 ADORA1 (0.44) ALDH1A1LMNAADORA1TMIGD3KDM4E
SCHEMBL28374611 0.68 STK4 (0.36) ALDH1A1LMNAADORA1TMIGD3KDM4E
SCHEMBL5065232 0.68 ADORA1 (0.43) ALDH1A1LMNAADORA1TMIGD3KDM4E
SCHEMBL6103621 0.68 ALDH1A1 (0.58) ALDH1A1LMNAADORA1TMIGD3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 US claimed
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Modema Therapeutics, Inc. (US) 2017-05-18 US claimed
EP-3157573-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2017-04-26 EP claimed
EP-3157572-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2017-04-26 EP claimed
CN-106170553-A Modified nucleic acid molecules and uses thereof 现代治疗公司 2016-11-30 CN claimed
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2016-10-20 US claimed
EP-3080289-A2 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2016-10-19 EP claimed
WO-2015196128-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-12-23 WO claimed
WO-2015196130-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-12-23 WO claimed
US-20150307542-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNATX, INC. 2015-10-29 US claimed
EP-2931319-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2015-10-21 EP claimed
WO-2015089511-A2 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-06-18 WO claimed
WO-2014093924-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2014-06-19 WO claimed
WO-2006076102-A2 FLUORESCENT NUCLEOSIDE ANALOGS THAT MIMIC NATURALLY OCCURRING NUCLEOSIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-07-20 WO claimed
US-20240360472-A1 POLYNUCLEOTIDES AND USES THEREOF STRAND THERAPEUTICS INC. (US) 2024-10-31 US disclosed
EP-4381080-A1 POLYNUCLEOTIDES AND USES THEREOF Strand Therapeutics Inc. (US) 2024-06-12 EP disclosed
US-20240165267-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2024-05-23 US disclosed
US-5440040-A Drug for Aids therapy; viricides MEDIVIR AB (SE) 1995-08-08 US disclosed
EP-0357571-A2 Pyrimidine nucleosides Medivir Aktiebolag (SE) 1990-03-07 EP disclosed
WO-1989012061-A1 PYRIMIDINE NUCLEOSIDES AND INTERMEDIATES MEDIVIR AB (SE) 1989-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 ALDH1A1 1969/4885LMNA 422/4885ADORA1 751/4885
US-20240165267-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 ALDH1A1 1969/4885LMNA 422/4885ADORA1 751/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 ALDH1A1 2324/4885LMNA 571/4885ADORA1 840/4885
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 ALDH1A1 2324/4885LMNA 571/4885ADORA1 840/4885
US-20150307542-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 ALDH1A1 1969/4885LMNA 422/4885ADORA1 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.